AEs.
| Total No. of AEs (No. of Patients in Follow-Up) | Infections (Type) | Cardiovascular Events (Type) | Other (Type) | Discontinuation (Reason)/ Temporary Suspension | |
|---|---|---|---|---|---|
| T4 | 6 (26) | 5 (3 upper respiratory tract, 1 urinary tract, 1 HSV) | 1 (paroxysmal supraventricular tachycardia) | 0 | 0/1 |
| T12 | 7 (24) | 5 (2 urogenital tract, 1 gastroenteritis, 1 COVID-19, 1 herpes zoster) | 1 (pulmonary thromboembolism) | 1 (neutropenia) | 0/4 |
| T24 | 5 (19) | 4 (1 urogenital tract, 1 gastroenteritis, 2 COVID-19) | 0 | 1 (fatigue) | 0/1 |
| T36 | 5 (14) | 5 (2 upper respiratory tract, 1 urogenital tract, 1 cellulitis, 1 COVID-19) | 0 | 0 | 1 (recurrence of infection)/1 |
| T48 | 3 (7) | 3 (1 oral candidiasis, 1 upper respiratory tract, 1 COVID-19) | 0 | 0 | 0/1 |
| T72 | 1 (1) | 1 (upper respiratory tract) | 0 | 0 | 0/0 |
| Total | 27 | 23 | 2 | 2 | 1/8 |
AE: adverse event; COVID-19: coronavirus disease 2019; HSV: herpes simplex virus; T: week.